Cequa™ (formerly Seciera™) - Dry Eye Syndrome

Auven Therapeutics completed discovery and development of Cequa™ (cyclosporine ophthalmic solution) for the treatment of Dry Eye disease and has sold Cequa™ to Sun Pharmaceuticals after completion by Auven of the last 2 phase 3 trials. Cequa™ is approved in the US and should be launched imminently. Sun Pharmaceuticals has the Worldwide rights, while Auven retains significant milestone and royalty interests extending through the patent life of Cequa.